Comparative Pharmacology
Head-to-head clinical analysis: AMARYL versus GLUCAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMARYL versus GLUCAMIDE.
AMARYL vs GLUCAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonylurea that stimulates insulin secretion from pancreatic beta cells by binding to the sulfonylurea receptor (SUR1) on ATP-sensitive potassium channels, causing channel closure and calcium influx.
Glucamide (glyburide) is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by binding to the sulfonylurea receptor (SUR1) on the ATP-sensitive potassium channel (K-ATP), leading to membrane depolarization, calcium influx, and exocytosis of insulin. It may also increase peripheral insulin sensitivity and reduce hepatic glucose production.
Initial dose 1-2 mg orally once daily, titrated to target glucose. Maximum dose 8 mg daily.
50 mg orally twice daily, increased to 100 mg twice daily after 4 weeks if tolerated
None Documented
None Documented
Terminal elimination half-life is 5-7 hours; clinically, dosing is once daily due to sustained glucose-lowering effect beyond half-life.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; extends to 12-18 hours in moderate renal impairment (CrCl 30-60 mL/min) and up to 24-36 hours in severe renal impairment (CrCl <30 mL/min); clinical context: duration of hypoglycemic effect correlates with half-life in renal impairment.
Approximately 60% excreted renally as metabolites (mainly M1 and M2) and 40% in feces; <1% excreted unchanged.
Primarily renal excretion of unchanged drug (70-80%) and glucuronide conjugate (10-15%); biliary/fecal excretion accounts for 5-10%.
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic